Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Ovid Therapeutics (Nasdaq: OVID), a biopharmaceutical company focused on developing medicines for brain conditions, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will deliver a virtual presentation on Wednesday, February 12, 2025, at 4:00 p.m. ET.
Interested parties can access the live webcast through the Events & Presentations section on the company's investor website at investors.ovidrx.com. For those unable to attend the live session, an archived replay will be made available on the company's website after the presentation.
Ovid Therapeutics (Nasdaq: OVID), una compagnia biofarmaceutica specializzata nello sviluppo di farmaci per le condizioni cerebrali, ha annunciato la sua prossima partecipazione alla 35ª Conferenza Annuale sulle Scienze della Vita di Oppenheimer. La direzione dell'azienda terrà una presentazione virtuale mercoledì 12 febbraio 2025, alle 16:00 ET.
Le parti interessate possono accedere alla trasmissione in diretta attraverso la sezione eventi e presentazioni sul sito web per investitori dell'azienda all'indirizzo investors.ovidrx.com. Per coloro che non possono partecipare alla sessione dal vivo, sarà disponibile una registrazione archiviata sul sito web dell'azienda dopo la presentazione.
Ovid Therapeutics (Nasdaq: OVID), una empresa biofarmacéutica centrada en el desarrollo de medicamentos para afecciones cerebrales, ha anunciado su próxima participación en la 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer. La dirección de la compañía realizará una presentación virtual el miércoles 12 de febrero de 2025, a las 4:00 p.m. ET.
Las partes interesadas pueden acceder a la transmisión en vivo a través de la sección de Eventos y Presentaciones en el sitio web para inversores de la compañía en investors.ovidrx.com. Para aquellos que no puedan asistir a la sesión en vivo, se pondrá a disposición una grabación archivada en el sitio web de la compañía después de la presentación.
오비드 테라퓨틱스 (Nasdaq: OVID)는 뇌 질환 치료제를 개발하는 바이오 제약 회사로, 오펜하이머 제35회 연례 헬스케어 생명 과학 회의에 참가할 예정이라고 발표했습니다. 회사 경영진은 2025년 2월 12일 수요일 오후 4시(ET)에 가상 발표를 진행할 것입니다.
관심 있는 분들은 회사의 투자자 웹사이트인 investors.ovidrx.com의 이벤트 및 발표 섹션을 통해 생중계에 접근할 수 있습니다. 실시간 세션에 참석하지 못하는 경우, 발표 후 회사 웹사이트에 아카이브된 재생본이 제공됩니다.
Ovid Therapeutics (Nasdaq: OVID), une entreprise biopharmaceutique axée sur le développement de médicaments pour les affections cérébrales, a annoncé sa prochaine participation à la 35e Conférence Annuelle sur les Sciences de la Vie organisée par Oppenheimer. La direction de l'entreprise présentera une présentation virtuelle le mercredi 12 février 2025, à 16h00 ET.
Les parties intéressées peuvent accéder à la diffusion en direct par le biais de la section Événements et Présentations sur le site des investisseurs de l'entreprise à l'adresse investors.ovidrx.com. Pour ceux qui ne peuvent pas assister à la session en direct, un enregistrement archivé sera disponible sur le site de l'entreprise après la présentation.
Ovid Therapeutics (Nasdaq: OVID), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Medikamenten für Hirnerkrankungen konzentriert, hat seine bevorstehende Teilnahme an der 35. Jahreskonferenz für Gesundheits- und Lebenswissenschaften von Oppenheimer bekannt gegeben. Das Management des Unternehmens wird am Mittwoch, den 12. Februar 2025, um 16:00 Uhr ET eine virtuelle Präsentation halten.
Interessierte können den Live-Stream über den Bereich Veranstaltungen und Präsentationen auf der Investoren-Website des Unternehmens unter investors.ovidrx.com abrufen. Für diejenigen, die an der Live-Sitzung nicht teilnehmen können, wird eine archivierte Aufzeichnung nach der Präsentation auf der Unternehmenswebsite zur Verfügung gestellt.
- None.
- None.
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that management will participate in a virtual presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 4:00 p.m. ET.
A live webcast of the presentation can be accessed through the Events & Presentations section of the Company’s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company’s website following the live presentation.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, and a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders; and OV888/GV101, a highly selective ROCK2 inhibitor, for undisclosed neurovascular and neuro-inflammatory conditions. For more information about these and other Ovid research programs, please visit www.ovidrx.com.
Investor Relations:
Garret Bonney
617-735-6093
gbonney@ovidrx.com
FAQ
When is Ovid Therapeutics presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch Ovid Therapeutics' Oppenheimer Conference presentation?
Will there be a replay available of Ovid Therapeutics' Oppenheimer Conference presentation?
What is the format of Ovid Therapeutics' presentation at the Oppenheimer Conference 2025?
